GLP-1 receptor agonism is well established to slow gastric emptying, which can increase intra-gastric pressure and potentially promote acid reflux in susceptible individuals
Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets
The efficacy of the vial can be compromised by 20%, 50% or more due to one large temperature excursion
Think with an additive mindset
Its highly doubtful that all of the drugs people take will be for sale through this channel, Cubanski said
Its a licensed platform that connects users with real medical providers who can prescribe GLP-1 medications when clinically appropriate